Imaging: Prostate Cancer VL

F-18-Labeled DCFPyL in Patients With Metastatic Prostate Cancer Undergoing Treatment With ADT – Esther Mena Gonzalez

Details
In this presentation from Esther Mena Gonzalez, she discusses her team’s findings on the role of castration status or hormone-sensitive castrate-resistance data and androgen deprivation therapy (ADT) in the use of 18F DCFPyL PET/CT. She discussed the objective of her study to be to investigate the performance of 18F DCFPyL in her cohort of patients with documented metastatic prostate cancer who we...

PYLARIFY®, F 18-labeled PSMA Targeted PET Gains US FDA Approval - Michael Morris

Details
Michael Morris, MD joins Charles Ryan, MD in a discussion on the United States (US) FDA Approval of PYLARIFY®, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent. The F 18 tracer went through two qualifying clinical trials the CONDOR trial and then OSPREY trial. This is the first time a national commercial approval will render PSMA i...

Bone Imaging in Metastatic Prostate Cancer: A Patient Education Video - Ephraim E. Parent

Details
In this patient-focused educational video, Ephraim Parent shares knowledge with patients on the role of skeletal imaging in prostate cancer. Dr. Parent covers the common ways imaging sans are done and, importantly how your physician applies this information to the treatment of metastatic prostate cancer. This video is provided by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Prosta...

The Accidental Journey of Shepherding PSMA PET Imaging in Prostate Cancer to the Clinic in the United States - Thomas Hope

Details
Thomas Hope, MD highlights how he came to study somatostatin receptor-based molecular Imaging for neuroendocrine tumors (NET). He takes us back to 2013, to the World Theranostics Conference at Hopkins, focused on neuroendocrine tumors because at that time there were no prostate theranostics. For this work, they put together a gallium dotatate program, which required the same synthesis module requi...

Improving Quality Imaging in Prostate Cancer with Gallium 68 PSMA-11 - Johannes Czernin

Details
68 Ga-PSMA-11, the first drug for PET imaging of prostate-specific membrane antigen (PSMA)–positive lesions in men with prostate cancer (PC), was approved on December 1, 2020, by the United States Federal Drug Administration (FDA). Joining Phillip Koo is Johannes Czernin, one of the original pioneers who started the process of getting gallium-68 PSMA approved in the United States. Dr. Czernin deta...

PSMA PET Imaging for Prostate Cancer Patient Education - Robert Flavell

Details
In this special patient-centered educational video from the Society of Nuclear Medicine and Molecular Imaging (SNMMI), Robert Flavell, an Assistant Professor and the Chief of Molecular Imaging and Therapeutics at the University of California in San Francisco presents on PSMA PET imaging. Dr. Flavell's lecture focuses on how PSMA PET is used in diagnosing prostate cancer and presents a case study o...

The Impact on Patient Care and Clinical Outcomes Gallium 68 PSMA-11 in Suspected Prostate Cancer Metastasis - Jeremie Calais

Details
On December 1, 2020, the US Food and Drug Administration approved Gallium 68 PSMA-11 (Ga 68 PSMA-11) for use for patients with suspected prostate cancer metastasis in UCLA and UCSF. It is the first drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. In a follow-up conversation after speaking about the approv...

68Ga-PSMA-11 PET approved in Biochemical Recurrent Prostate Cancer - Jeremie Calais

Details
Jeremie Calais, MD, MSc, joins Phillip Koo, MD, FACS, to discuss the approval of Gallium 68 PSMA-11, the first agent for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. The safety and efficacy of Ga 68 PSMA-11 were evaluated in two prospective clinical trials, which lead to the United States Federal Drug Administ...

68Ga-PSMA-11 Joins FDA-Approved Tools for Management of Prostate Cancer - Thomas Hope

Details
68 Ga-PSMA-11, the first drug for PET imaging of prostate-specific membrane antigen (PSMA)–positive lesions in men with prostate cancer (PC), was FDA approved on December 1, 2020. The approval was granted to the University of California–San Francisco (UCSF) and UC–Los Angeles (UCLA). 68 Ga-PSMA-11 is indicated for suspected metastatic disease at the time of initial staging prior to definitive ther...

Limitations of PET Imaging in Prostate Cancer - Stefano Fanti

Details
Stefano Fanti joins Phillip Koo in conversation on establishing the PSMA PET/CT, as the gold standard with regards to imaging for prostate cancer, expectations, accuracy when it comes to imaging, how that CT should be performed, and limitations with regards to trial design for diagnostic imaging agents. Dr. Fanti offers advice for nuclear medicine physicians and radiologists in the community with...